6 March 2014
Protein reelin rescues cognitive impairment in animal models of Alzheimerís disease
The study describes the neuroprotective effect of reelin in neurodegenerative diseases.
Co-directed by Eduardo Soriano and Lluís Pujadas, from the University of Barcelona, and the CIBERNED network, the study has involved Bernat Serra-Vidal, Ernest Giralt and Natàlia Carulla, all three scientists at IRB.
5 March 2014
IRB to develop an innovation project on bone metastasis
ICREA researcher Roger Gomis at IRB receives technology valorisation funding from the Generalitat de Catalunya.
This funding seeks to faciliatate the success of technology transfer to the market.
27 February 2014
Researchers reveal the dual role of brain glycogen
Two articles produced by Joan Guinovart’s lab answer key questions regarding the activity of glycogen in neurons.
An excess of glycogen causes neuronal death while a lack of this polysaccharide endangers these cells under oxygen shortage to the brain.
24 February 2014
A step closer to putting together the vital puzzle of the bacteria Escherichia coli
E. coli is the best known model organism at the molecular level. It is used extensively for biotechnology production, and its infectious strains are of biomedical interest.
The article in Nature Biotecnology is a collaborative effort between biologists, biochemists and bioinformaticians at the Craig Venter Institute, the University of Virginia, and the Institute for Research in Biomedicine (IRB).
The team of 18 researchers presents the first map of key interactions between the molecular components of the bacteria, and allow us to understand how its most intimate machinery works.
20 February 2014
Three Severo Ochoa Centres of Excellence join efforts in computational biology
BSC, CRG, and IRB sign a collaboration agreement for five years that will promote Barcelona as a world leader in computational biology.
The goals of this joint programme are to retain the critical mass of researchers, to attract talent, and to boost computational biology.
The team includes ten well-known researchers headed by Modesto Orozco (IRB), Roderic Guigó (CRG), and David Torrents (BSC).
19 February 2014
Scientists discover a new kind of DNA intercalator
DNA intercalators developed for use in chemotherapy interfere with the DNA of cancer cells, thus eliminating them.
Researchers at IRB, in collaboration with a team in Sweden, publish the study in Angewandte Chemie.
14 February 2014
Eduard Batlle winner of the Pezcoller Foundation- EACR Cancer Research Award
The leader of the Colorectal Cancer Lab will give a plenary lecture at EACR-23
11 February 2014
First observation of a human HAT, key proteins in numerous pathologies
Researchers at IRB Barcelona, BSC, and the University of Bern observe the first structure of a human HAT at low resolution.
HAT amino acid transporters are involved in pathologies such as aminoacidurias, cancer, viral infections and cocaine addiction.
The breakthrough published in the Proceedings of the National Academy of Science USA allows researchers to delve into the functions of HATs and to address the rational drug design of inhibitors.
The study has been partially funded by the European project EDICT (European Drug Initiative on Channels and Transporters), devoted to increasing the number of membrane protein structures available.
30 January 2014
Scientists unveil a molecular mechanism that controls plant growth and development
Researchers at IRB and IBMB-CSIC, in Barcelona, and at the University of Wageningen, in the Netherlands, reveal how auxin hormone-regulated proteins activate developmental genes in plants.
Auxins are key components of plant growth and have many applications in agriculture. The biomedical application of these hormones are also being addressed.
The study is published today in the scientific journal Cell.
28 January 2014
International patient advocates partner to fund Spanish gene-therapy project to treat Friedreich's ataxia
Scientists at the Institute for Research in Biomedicine (IRB) and the “Centro de Biología Molecular Severo Ochoa” (CBMSO) launched the project two months ago.
The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.
The support provided by FARA will account for 50% of the project budget of 300,000 euros. Of note, FARA’s funds come from the support of patient families and communities raising funds at a grassroots level and from other International advocates such as FARA – Ireland.